Stanislava Macura

616 total citations · 1 hit paper
9 papers, 426 citations indexed

About

Stanislava Macura is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Stanislava Macura has authored 9 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in Stanislava Macura's work include Metabolism, Diabetes, and Cancer (7 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (4 papers). Stanislava Macura is often cited by papers focused on Metabolism, Diabetes, and Cancer (7 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (4 papers). Stanislava Macura collaborates with scholars based in Denmark, United States and Canada. Stanislava Macura's co-authors include Ildiko Lingvay, Juan P. Frías, Sue D. Pedersen, Chantal Mathieu, Srikanth Deenadayalan, Melanie J. Davies, Lars Erichsen, Filip K. Knop, ANETTE L. SØNDERGAARD and Nikolaοs Tentolouris and has published in prestigious journals such as The Lancet, Diabetes and The Lancet Diabetes & Endocrinology.

In The Last Decade

Stanislava Macura

8 papers receiving 412 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

2023 193 citations Juan P. Frías, Srikanth Deenadayalan et al. The Lancet profile →

Peers

Stanislava Macura

EDM

MB

PHARM

SURGE

PHYSI

Srikanth Deenadayalan Denmark

Thalia Panagiotopoulou Greece

J. Han United States

Christine Roy-Duval United States

G. Kemmeries Germany

T Le-Thi Denmark

Sohini Raha United States

J.P. Courrèges France

Sayeh Tadayon Denmark

Rajaa Nahra United States

Srikanth Deenadayalan Denmark

Stanislava Macura

485 ×1.4

EDM

274 ×1.7

MB

154 ×1.1

PHARM

130 ×1.3

SURGE

88 ×0.9

PHYSI

Citations per year, relative to Stanislava Macura Stanislava Macura (= 1×) peers Srikanth Deenadayalan

Countries citing papers authored by Stanislava Macura

Since Specialization

Citations

This map shows the geographic impact of Stanislava Macura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanislava Macura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanislava Macura more than expected).

Fields of papers citing papers by Stanislava Macura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanislava Macura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanislava Macura. The network helps show where Stanislava Macura may publish in the future.

Co-authorship network of co-authors of Stanislava Macura

This figure shows the co-authorship network connecting the top 25 collaborators of Stanislava Macura. A scholar is included among the top collaborators of Stanislava Macura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanislava Macura. Stanislava Macura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Melgaard, Anita E., et al.. (2024). 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing. Diabetes. 73(Supplement_1).

2.

Frías, Juan P., Srikanth Deenadayalan, Lars Erichsen, et al.. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 402(10403). 720–730. 193 indexed citations breakdown →

3.

Frías, Juan P., Pernille Auerbach, Harpreet S. Bajaj, et al.. (2021). Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology. 9(9). 563–574. 113 indexed citations

4.

Lingvay, Ildiko, Thomas K. Hansen, Stanislava Macura, et al.. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Research & Care. 8(2). e001706–e001706. 43 indexed citations

5.

Aroda, Vanita R., Matthew Capehorn, Louis Chaykin, et al.. (2019). Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials. Diabetes Obesity and Metabolism. 22(3). 303–314. 20 indexed citations

6.

Macura, Stanislava, et al.. (2016). Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST^®: SIMPLE USE). Diabetic Medicine. 34(2). 174–179. 7 indexed citations

7.

Bebakar, Wan Mohamad Wan, et al.. (2015). Treatment Intensification with Insulin Degludec/Insulin Aspart Twice Daily: Randomized Study to Compare Simple and Step-Wise Titration Algorithms. Endocrine Practice. 22(5). 546–554. 10 indexed citations

8.

Franek, Edward, Martin Haluzı́k, Mehmet Sargın, et al.. (2015). Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes. Diabetic Medicine. 33(4). 497–505. 38 indexed citations

9.

Franek, Edward, Martin Haluzı́k, Mehmet Sargın, et al.. (2014). PO231 IDEGASP PROVIDES SUPERIOR FPG CONTROL AND REDUCED HYPOGLYCEMIA VS BIASP 30 IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES: A RANDOMIZED PHASE 3 TRIAL. Diabetes Research and Clinical Practice. 106. S166–S167. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact